Paris, 21 November 2017, 5.45 pm Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine Phase 3 clinical studies on-going for masitinib-gemcitabine combination in pancreatic cancer, refractory peripheral T-cell lymphoma and refractory ovarian...
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m. Eastern Time
Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Dr. Gabriel Mbalaviele presented data from pre-clinical studies of Aclaris...
SAN FRANCISCO- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were present
AIT Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that management will hold a clinical update meeting on November 28, 2017 at 7:30 a.m. to discuss data from its NO-NTM Phase 2 clinical t
ENGLEWOOD, Colo.- Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension study of Ampion in patients with severe osteoarthritis of the knee. The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial. This OLE study will address the regulatory requ
WESTMINSTER, Colo.- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office's issuance of a patent on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide...
On November 21, 2017, Ardelyx, Inc. provided an update on the development of its cardiorenal pipeline with a focus on tenanpanor and next-generation opportunities. Following learnings from the Company's first completed Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, the Company soug
New Delhi, India 11/20/2017 About DelveInsight. DelveInsight is a leading Market Research and Business Consulting firm focused exclusively on life sciences. It supports companies by providing end to end comprehensive solutions to improve their performance and in making long-lasting decision for their businesses.
Four years ago, radium-223 dichloride was the first therapeutic alpha-emitting radionuclide to be approved by the Food and Drug Administration for clinical use in cancer patients. A Cornell team led by Justin Wilson, assistant professor in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and John Babich, profess
Biocon Ltds shares jumped over 7% after the company said on Monday that its manufacturing facility in Bengaluru, which had received observations relating to lapses in quality compliance earlier this year, has been cleared by the US Food and Drug Administration. The US FDA has issued an Establishment Inspection Report in relation to the cGMP inspect
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Initiation of two additional Phase 1 b/2 studies under collaboration with Genentech, following the first study which was initiated in July 2017. All studies are explorin
The FDA has created a policy framework for cellular therapies and other regenerative medicines by releasing two draft and two final guidance documents. In the guidance, the FDA takes the RMAT status created by the 21st Century Cures Act, contextualizes it against other regulatory designations and explains how and why companies may want to apply.
PETACH TIKVA, Israel- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, Can-
Cancer Prevention Pharmaceuticals, a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29 th Annual Healthcare Conference on November 28, 7:50 -8: 10 a.m. ET at the Lotte New York Palace in New York City. In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. th
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 2:00pm ET at the Lotte New York Palace in New York, NY.
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety,...
CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits. 99.1 Press release issued by the Company on November21, 2017. 2 CATALYST PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d485575dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Phase 2 Study of
-Celsion Corporation today announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound 2017 5:28. The TARDOX Study, whic
The US Biologics License Application was submitted by Genentech, a member of Roche Group. 'We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,' said Chugai's President& COO, Tatsuro Kosaka.' HEMLIBRA is a first in class biopharmaceutical which is
India, Mumbai- Cipla Ltd, a global pharmaceutical company, today announced that it has received final approval for its Abbreviated New Drug Application for Budesonide Inhalation Suspension, 0.25 mg/2mL, 0.5 mg/2mL, and 1 mg/2mL from the United States Food and Drug Administration to market a generic version of Astrazeneca's Pulmicort Respules.
London, Ontario and Boston, MA- Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacokinetic data from the dose-escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies that support the continued developme
Cytokinetics, Incorporated today announced that VITALITY-ALS, the international Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis, did not meet the primary endpoint of change from baseline in slow vital capacity which was evaluated at 24 weeks following randomization or any of the secondary endpoints in the trial
Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Other EventsItem 8.01. Other Events. CYTOKINETICS INC ExhibitEX-99.1 2 exh-991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Cytokinetics Announces Negative Results From VITALITY-ALS Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Pr
Copenhagen, Denmark; November 21, 2017 Genmab A/S announced today that data from the Phase III ALCYONE study of daratumumab in combination with bortezomib, melphalan and prednisone versus VMP alone treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation, which was submitted by our collaborat